Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?

Lancet Gastroenterol Hepatol. 2024 May;9(5):402-405. doi: 10.1016/S2468-1253(23)00406-5. Epub 2024 Feb 22.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Crohn Disease* / drug therapy
  • Humans
  • Immunologic Factors / adverse effects
  • Infliximab / therapeutic use

Substances

  • Infliximab
  • Immunologic Factors
  • Antibodies, Monoclonal